Clinical Trials Browser

Phase 2 × Breast Neoplasms, Male × Docetaxel × Clear all

NCT00820872 2019-10-21

Docetaxel, Carboplatin, Trastuzumab, and Lapatinib in Treating Patients With Early Stage Breast Cancer

Phase 2 Completed

30 enrolled 6 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT00852332 2018-07-24

Docetaxel With or Without a Phytochemical in Treating Patients With Breast Cancer

Phase 2 Terminated

Breast Neoplasms, Breast Neoplasms, Male

NCT00079118 2016-12-13

Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer

Phase 2 Completed

Breast Neoplasms, Breast Neoplasms, Male

NCT00088998 2016-12-07

Docetaxel, Capecitabine, and Bevacizumab in Treating Patients With Metastatic Breast Cancer

Phase 2 Completed

Breast Neoplasms, Breast Neoplasms, Male

NCT00107510 2016-07-06

Docetaxel, Carboplatin, and Pegfilgrastim in Treating Patients Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer

Phase 2 Completed

Breast Neoplasms, Breast Neoplasms, Male

NCT00054275 2016-02-17

Erlotinib Plus Docetaxel in Treating Patients With Stage IV or Recurrent Breast Cancer

Phase 2 Completed

39 enrolled 7 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT00027885 2013-06-17

Phase II Bevacizumab + Tax In Advanced Breast Cancer

Phase 2 Completed

Breast Neoplasms, Breast Neoplasms, Male

NCT00044993 2013-05-30

Chemotherapy Combined With Gene Therapy in Treating Patients Who Have Stage III or Stage IV Breast Cancer

Phase 2 Completed

Breast Neoplasms, Breast Neoplasms, Male